Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Pharmaceutical QMS Guidelines in 2026: GMP Requirements, Compliance Systems, and Inspection Readiness

Pharmaceutical quality system guidelines in 2026 define GMP-based compliance expectations, focusing on inspection readiness, CAPA effectiveness, and data integrity. These frameworks support pharmaceutical organizations in building robust quality governance and risk-based quality management systems aligned with ICH Q10 principles.
  • Blog, Quality Management System
Pharmaceutical quality system guidelines showing GMP quality system requirements, inspection readiness, CAPA effectiveness, data integrity GMP compliance, and pharmaceutical quality governance framework in regulated pharma operations.

FDA’s New Rare Disease Framework; What Counts as Enough Evidence?

The FDA’s proposed Plausible Mechanism Framework for rare disease therapies is entering a new phase of uncertainty following leadership changes at the agency. While regulators continue to support faster pathways for ultra-rare treatments, pharmaceutical companies still lack clarity on how
  • News
FDA’s New Rare Disease Framework; What Counts as Enough Evidence?

FDA Blocks PRC2 Drug Path; Fulcrum Cuts 85% Workforce After Collapse

A major restructuring has hit Fulcrum Therapeutics after the company halted development of its lead sickle cell therapy following FDA-linked safety concerns. The biotech will reduce its workforce by around 85%, leaving only nine employees, as regulatory risk tied to
  • News
FDA Blocks PRC2 Drug Path; Fulcrum Cuts 85% Workforce After Collapse

Pharma Quality Management in 2026: GMP Systems, Risks, and Compliance Frameworks

This article explores the pharma quality management system, focusing on GMP compliance frameworks, quality risk management, CAPA effectiveness, and data integrity. It explains how modern pharmaceutical organizations build resilient quality systems to ensure inspection readiness and regulatory performance in highly
  • Blog, Quality Management System
Pharmaceutical quality management system in the pharmaceutical industry showing GMP compliance framework, quality risk management, CAPA system, data integrity, and continuous improvement within a digital biotech manufacturing environment.

Billions Chase Lung Cancer; Yet Liver Cancer Steals the Spotlight

Pharmaceutical companies continue to pour billions into PD-1/VEGF bispecific antibodies after strong lung cancer results fueled industry enthusiasm. However, analysts increasingly question whether the sector is targeting the most valuable opportunity. As global Phase 3 programs expand, emerging evidence suggests
  • News
Billions Chase Lung Cancer; Yet Liver Cancer Steals the Spotlight

China Becomes Pharma Powerhouse; RA Capital Swiftbridge Triggers Global Shift

RA Capital has launched Swiftbridge, a new initiative designed to give its biotech portfolio companies structured access to China’s clinical trial ecosystem. Introduced in mid-2025, the program removes a key bottleneck in global drug development by simplifying entry into China’s
  • News
China Becomes Pharma Powerhouse; RA Capital Swiftbridge Triggers Global Shift

Takeda Pay-for-Delay Shock; $2.5B Verdict Wipes Profit Into Loss

A U.S. federal jury in Boston has ruled against Takeda in a pay-for-delay antitrust case involving its constipation drug Amitiza, forcing the company to book a $2.5 billion legal provision and swing to a FY2025 net loss. The decision marks
  • News
Takeda Pay-for-Delay Shock; $2.5B Verdict Wipes Profit Into Loss

U.S. and China AI Drug Race Is Breaking Regulatory Control; FDA Pressure and Data Failures Are Escalating Fast

At BioSpace’s NextGen 2026 discussion, leading biotech executives from the United States and China highlighted a growing strategic divide in pharmaceutical innovation. The conversation revealed how artificial intelligence is now accelerating drug discovery and clinical decision-making, while simultaneously exposing weaknesses
  • News
U.S. and China AI Drug Race Is Breaking Regulatory Control; FDA Pressure and Data Failures Are Escalating Fast